Biomarkers and surrogate endpoints in clinical trials


  • Thomas R. Fleming,

    Corresponding author
    • Department of Biostatistics, University of Washington, Seattle, WA, USA
    Search for more papers by this author
  • John H. Powers

    1. Scientific Applications International Corporation-Frederick, Frederick, MD, USA
    2. National Institutes of Health (NIH), Bethesda, MD, USA
    3. George Washington University School of Medicine, Washington, DC, USA
    Search for more papers by this author

Thomas Fleming, Department of Biostatistics, University of Washington, Box 357232 Seattle, WA 98195, USA.



One of the most important considerations in designing clinical trials is the choice of outcome measures. These outcome measures could be clinically meaningful endpoints that are direct measures of how patients feel, function, and survive. Alternatively, indirect measures, such as biomarkers that include physical signs of disease, laboratory measures, and radiological tests, often are considered as replacement endpoints or ‘surrogates’ for clinically meaningful endpoints. We discuss the definitions of clinically meaningful endpoints and surrogate endpoints, and provide examples from recent clinical trials. We provide insight into why indirect measures such as biomarkers may fail to provide reliable evidence about the benefit-to-risk profile of interventions. We also discuss the nature of evidence that is important in assessing whether treatment effects on a biomarker reliably predict effects on a clinically meaningful endpoint, and provide insights into why this reliability is specific to the context of use of the biomarker. Copyright © 2012 John Wiley & Sons, Ltd.